Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04399681
Recruitment Status : Recruiting
First Posted : May 22, 2020
Last Update Posted : May 22, 2020
Sponsor:
Information provided by (Responsible Party):
Ramazan Guven, Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary:
Novel Coronavirus 2019 Disease (COVID-19) mortality is highly associated with viral pneumonia and its complications. Accurate and prompt diagnosis shown to be effective to improve outcome by providing early treatment strategies. While chest X-ray (CXR) and computerized tomography (CT) are defined as gold standard, given the advantage of being an ionized radiation free, practical technique point of care ultrasound (POCUS) is also reported as a diagnostic tool for COVID-19. There are limited studies regarding the importance of POCUS in diagnosis and review of COVID-19. Therefore the aim of this study is to evaluate the utility of bedside lung ultrasound on diagnosis of COVID-19 for patients admitted to emergency department .

Condition or disease Intervention/treatment Phase
COVID Pneumonia, Viral Device: Bedside lung ultrasound Not Applicable

Detailed Description:
Novel Coronavirus 2019 Disease (COVID-19) mortality is highly associated with viral pneumonia and its complications. Accurate and prompt diagnosis shown to be effective to improve outcome by providing early treatment strategies. While chest X-ray (CXR) and computerized tomography (CT) are defined as gold standard, given the advantage of being an ionized radiation free, practical technique point of care ultrasound (POCUS) is also reported as a diagnostic tool for COVID-19. There are limited studies regarding the importance of POCUS in diagnosis and review of COVID-19. Therefore the aim of this study is to evaluate the utility of bedside lung ultrasound on diagnosis of COVID-19 for patients admitted to emergency department .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department
Actual Study Start Date : May 10, 2020
Estimated Primary Completion Date : August 10, 2020
Estimated Study Completion Date : September 10, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia Ultrasound

Arm Intervention/treatment
Suspected COVID-19 Group
Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
Device: Bedside lung ultrasound
Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.




Primary Outcome Measures :
  1. Presence of viral pneumonia caused by COVID 19 [ Time Frame: 3 months ]
    Efficacy of POCUS on diagnosis of viral pneumonia caused by COVID 19



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients with an informed consent
  • Admission to emergency department with symptoms or signs of COVID-19

Exclusion Criteria:

  • Absence of informed consent
  • Patients under age of 18
  • Presence of acute coronary syndrome
  • Presence of chronic lung disease
  • Pregnancy
  • Presence of trauma
  • Patients with a diagnosis of malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04399681


Contacts
Layout table for location contacts
Contact: Ramazan Guven +902124041500 drramazanguven@gmail.com
Contact: Seda Yilmaz Semerci +905337180683 sedayilmazsemerci@gmail.com

Locations
Layout table for location information
Turkey
Istanbul Kanuni Sultan Suleyman Training and Research Hospital Recruiting
Istanbul, Turkey, 34303
Contact: Seda Yilmaz Semerci    +905337180683    sedayilmazsemerci@gmail.com   
Sponsors and Collaborators
Kanuni Sultan Suleyman Training and Research Hospital
Layout table for additonal information
Responsible Party: Ramazan Guven, Professor, Kanuni Sultan Suleyman Training and Research Hospital
ClinicalTrials.gov Identifier: NCT04399681    
Other Study ID Numbers: KSSEAH--
First Posted: May 22, 2020    Key Record Dates
Last Update Posted: May 22, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases